Wolverine Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Wolverine Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-64	Closed	-$9K	–	1334
2016 Q1	$9K	Buy	64 +54	+540%	+$3.17K	﹤0.01%	1078
2015 Q4	$1K	Buy	+10	New	+$618	﹤0.01%	1641
2015 Q3	–	Sell	-260	Closed	-$59K	–	1981
2015 Q2	$59K	Hold	260	–	–	﹤0.01%	1261
2015 Q1	$129K	Buy	260 +250	+2,500%	+$14.5K	﹤0.01%	990
2014 Q4	$2K	Hold	10	–	–	﹤0.01%	1993
2014 Q3	$1K	Hold	10	–	–	﹤0.01%	2388
2014 Q2	$1K	Sell	10 -5	-33%	-$256	﹤0.01%	2258
2014 Q1	$3K	Sell	15 -4	-21%	-$185	﹤0.01%	2077
2013 Q4	$5K	Hold	19	–	–	﹤0.01%	2367
2013 Q3	$3K	Sell	19 -91	-83%	-$3.55K	﹤0.01%	2481
2013 Q2	$7K	Buy	+110	New	+$4.28K	﹤0.01%	2297

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Wolverine Asset Management's TEVA Position: Q2 2026 in Review

Wolverine Asset Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 1 share worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Wolverine Asset Management first reported a position in TEVA in Q2 2013 and has held it in 36 quarters since. The position peaked at $13.6M in Q2 2018. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Wolverine Asset Management held 1 share of Teva Pharmaceuticals worth $34 as of Q2 2026.
Wolverine Asset Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1655 holding.
Wolverine Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
Wolverine Asset Management's Teva Pharmaceuticals position peaked at $13.6M in Q2 2018.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.